share_log

Exicure | NT 10-K: Others

Exicure | NT 10-K: Others

Exicure | NT 10-K:其他
美股SEC公告 ·  04/01 16:26
Moomoo AI 已提取核心信息
Exicure, Inc. has announced that it will not be able to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, within the prescribed time period. The delay is due to the company finalizing certain accounting treatments and completing necessary reviews. This includes the restatement of its financial statements for the first and second quarters of 2023, as well as completing and filing the related Form 10-Q amendments and its third quarter financial statements. Consequently, Exicure does not expect to meet the original filing deadline for the Annual Report. The company has also not yet filed its Form 10-Q for the third quarter of 2023. Exicure anticipates a significant change in its results of operations compared to the previous...Show More
Exicure, Inc. has announced that it will not be able to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, within the prescribed time period. The delay is due to the company finalizing certain accounting treatments and completing necessary reviews. This includes the restatement of its financial statements for the first and second quarters of 2023, as well as completing and filing the related Form 10-Q amendments and its third quarter financial statements. Consequently, Exicure does not expect to meet the original filing deadline for the Annual Report. The company has also not yet filed its Form 10-Q for the third quarter of 2023. Exicure anticipates a significant change in its results of operations compared to the previous fiscal year, which will be reflected in the earnings statements. This change is attributed to a major reduction in workforce, suspension of preclinical activities, and cessation of all research and development activities announced in September 2022, as the company explores strategic alternatives. While research and development expenses have substantially decreased, general and administrative expenses are expected to be higher than the previous year. The notification was signed by Paul Kang, Chief Executive Officer, on April 1, 2024.
Exicure, Inc.宣布,它将无法在规定的期限内提交截至2023年12月31日财年的10-K表年度报告。延迟是由于该公司完成了某些会计处理并完成了必要的审查。这包括重报其2023年第一和第二季度的财务报表,以及完成和提交相关的10-Q表修正案及其第三季度财务报表。因此,Exicure预计不会在年度报告的原始提交截止日期之前提交。该公司也尚未提交2023年第三季度的10-Q表格。Exicure预计,与上一财年相比,其经营业绩将发生重大变化,这将反映在收益报表中。这一变化归因于公司在探索战略替代方案时于2022年9月宣布大幅裁员、暂停临床前活动以及停止所有研发活动。尽管研发费用已大幅减少,但一般和管理费用预计将高于上一年。该通知由首席执行官保罗·康于2024年4月1日签署。
Exicure, Inc.宣布,它将无法在规定的期限内提交截至2023年12月31日财年的10-K表年度报告。延迟是由于该公司完成了某些会计处理并完成了必要的审查。这包括重报其2023年第一和第二季度的财务报表,以及完成和提交相关的10-Q表修正案及其第三季度财务报表。因此,Exicure预计不会在年度报告的原始提交截止日期之前提交。该公司也尚未提交2023年第三季度的10-Q表格。Exicure预计,与上一财年相比,其经营业绩将发生重大变化,这将反映在收益报表中。这一变化归因于公司在探索战略替代方案时于2022年9月宣布大幅裁员、暂停临床前活动以及停止所有研发活动。尽管研发费用已大幅减少,但一般和管理费用预计将高于上一年。该通知由首席执行官保罗·康于2024年4月1日签署。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息